CAJ | 학술논문

目的：探讨拉米夫定联合阿德福韦酯联合治疗对乙型肝炎相关性肝癌生存的影响。方法：回顾性分析2008年7月至2011年1月以来我院门诊及住院的55例HBV-DNA阳性的原发性肝癌患者，治疗组30例，对照组25例，两组均给予相同的针对肿瘤的治疗，治疗组应用拉米夫定联合阿德福韦酯抗病毒治疗，对照组不给于抗病毒治疗。采用log rank检验两组生存时间差异，用Kaplan-Meier绘制患者生存曲线。结果：治疗组患者生存时间高于对照组，两组差异有显著性（ P＜0．05）。结论：拉米夫定联合阿德福韦酯治疗乙肝相关性肝癌术后患者可以延长患者的生存期。
목적：탐토랍미부정연합아덕복위지연합치료대을형간염상관성간암생존적영향。방법：회고성분석2008년7월지2011년1월이래아원문진급주원적55례HBV-DNA양성적원발성간암환자，치료조30례，대조조25례，량조균급여상동적침대종류적치료，치료조응용랍미부정연합아덕복위지항병독치료，대조조불급우항병독치료。채용log rank검험량조생존시간차이，용Kaplan-Meier회제환자생존곡선。결과：치료조환자생존시간고우대조조，량조차이유현저성（ P＜0．05）。결론：랍미부정연합아덕복위지치료을간상관성간암술후환자가이연장환자적생존기。
Objective: To analyze the clinical factors predicting long-term survival after combination therapy of lamivudine with adefovir dipivoxil in hepatic carcinoma related to hepatitis B .Method:The clini-cal data of 55 patients with hepatic carcinoma who underwent combination therapy of lamivudine with adefovir dipivoxil from 2009 to 2012 were analyzed Retrospectively .The patients were divided into antiviral group ( 30 cases treated with lamivudine with adefovir dipivoxil ) and non-antiviral group ( 25 cases without antivirus therapy ) .Both of two group were treated with resection of liver cancer or transcatheter arterial chemoemboli-zation.Result:The survival time of antiviral group was longer than non-antiviral group(P<0.05).Conclu-sion:Combination therapy of lamivudine with adefovir dipivoxil in hepatic carcinoma related to hepatitis B can improve suvival time .